3-iodobenzylguanidine has been researched along with isotretinoin in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Caron, HN; de Kraker, J; Hoefnagel, KA; van Eck, B; van Santen, HM; Verschuur, AC | 1 |
| Cross, SF; Dalla Pozza, L; Munns, CF | 1 |
| Alazraki, A; Cash, T; Katzenstein, HM; Qayed, M | 1 |
3 other study(ies) available for 3-iodobenzylguanidine and isotretinoin
| Article | Year |
|---|---|
Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age.
Topics: 3-Iodobenzylguanidine; Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Drug Evaluation; Feasibility Studies; Female; Humans; Infant; Isotretinoin; Male; Neuroblastoma; Peripheral Blood Stem Cell Transplantation; Radiopharmaceuticals; Transplantation, Autologous; Treatment Outcome | 2008 |
Hypercalcemia and osteoblastic lesions induced by 13-Cis-retinoic acid mimicking relapsed neuroblastoma.
Topics: 3-Iodobenzylguanidine; Child; Humans; Hypercalcemia; Isotretinoin; Male; Neoplasm Recurrence, Local; Neuroblastoma; Osteoblasts | 2009 |
Prolonged Isotretinoin in Ultra High-Risk Neuroblastoma.
Topics: 3-Iodobenzylguanidine; Adrenal Gland Neoplasms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Drug Administration Schedule; Fatal Outcome; Female; Ganglioneuroblastoma; Hematopoietic Stem Cell Transplantation; Humans; Isotretinoin; Maintenance Chemotherapy; Male; Neuroblastoma; Remission Induction; Risk; Transplantation, Autologous | 2017 |